The Latest

  • An illustration for BioPharma Dive's deals database
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Deep Dive

    Biotech M&A is picking back up. Here are the latest deals.

    Fourteen acquisitions totaling $23 billion in value were announced in the second quarter, easily eclipsing the marks set during the same period last year and in 2020.

    Updated 11 hours ago
  • Sponsored by Medscape

    Connect to the conversation around mental health: A spotlight on physician burnout

    This year's report showed that 47% of physicians feel burned out, compared with 42% the year before.

  • Image attribution tooltip
    Jacob Bell

    Jazz drug fails in late-stage study for multiple sclerosis

    The drug, part of Jazz’s $7 billion acquisition of GW Pharmaceuticals, didn’t perform significantly better than placebo in treating the muscle spasticity that’s tied to the disease.

  • Rendered illustration of human DNA
    Image attribution tooltip
    DKosig via Getty Images
    Gene therapy safety

    Another Astellas gene therapy trial paused by FDA after side effect report

    The regulator suspended testing of Astellas’ Pompe disease treatment after one patient experienced peripheral nerve damage. Both of the pharma’s clinical-stage gene therapies are now on hold.

  • A scientist in a laboratory at Relay Therapeutics
    Image attribution tooltip
    Permission granted by Relay Therapeutics

    Relay details new research plans in quest to design better cancer drugs

    The biotech company revealed three new drug candidates for breast cancer, while laying out a path to regulators for its most advanced treatment.

  • Image attribution tooltip
    Sanofi Pasteur

    Sanofi, GSK say dual-acting vaccine prevents COVID-19 from omicron in large trial

    A shot the partners have been developing reduced symptomatic infections associated with the variant by 72% compared to a placebo, positioning it as a potential option, if approved, to combat omicron.  

  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Deep Dive

    After a record run, fewer biotechs are going public. Here's how they're performing.

    Only a handful of the 118 biotechs that have gone public since the start of 2021 trade above their offering price. Both of the two top performers, Belite Bio and Nuvectis Pharma, started out with small valuations.

    Updated June 27, 2022
  • Image attribution tooltip
    Getty Images

    Radius, maker of bone and cancer drugs, to be bought in take-private deal

    Two investment firms, Gurnet Point Capital and Patient Square Capital, have agreed to pay as much as $890 million for Radius, which has come under pressure amid share price declines.

  • A 3D illustration of a DNA double helix
    Image attribution tooltip
    libre de droit via Getty Images

    UniQure buoyed by early data for Huntington's gene therapy

    After one year, researchers detected important protein changes in patients who received a low dose of the experimental treatment. Further testing and functional data are needed to assess its potential, however.

  • Image attribution tooltip
    Novartis

    Novartis to invest $250M in tropical disease drug research

    The bulk of the investment will go toward advancing development of three antimalarial drug candidates meant to combat resistance to artemisinin, a common treatment.

    Updated June 23, 2022
  • Image attribution tooltip
    Courtesy of Galapagos

    Galapagos, with latest deals, charts an unexpected journey to cell therapy

    The Belgian drugmaker will spend more than $100 million to acquire two companies, CellPoint and AboundBio, in a move meant to “disrupt” CAR-T treatment.

  • Ajay Purohit, a Biogen employee, points to brain scans of people with Alzheimer's
    Image attribution tooltip
    Permission granted by Biogen

    Biogen, citing insurance challenges, shutters one of its Aduhelm studies

    The company says a recent coverage decision by Medicare has forced it to end an observational trial of the Alzheimer's drug after enrolling just 29 participants.

  • Image attribution tooltip
    Novartis

    Novartis hunting for sickle cell cure with Precision deal

    The pharma will pay $75 million to access Precision’s gene editing technology, adding another program to the lengthening list of drug development efforts targeting the inherited blood condition.

  • Image attribution tooltip
    Christopher Furlong via Getty Images

    Ionis, AstraZeneca claim success for competitor to Alnylam rare disease drug

    A medicine at the center of a multibillion-dollar alliance between the two companies passed a major test in transthyretin amyloidosis. Full study details were not disclosed, however. 

  • An illustration of necrotic muscle fiber in Duchenne muscular dystrophy.
    Image attribution tooltip
    Jose Luis Calvo Martin, Jose Enrique Garcia-Maurino Muzquiz via Getty Images

    Mixed results for PTC Duchenne drug put spotlight on EU approval

    A confirmatory study of PTC Therapeutics’ muscular dystrophy treatment Translarna missed its main goal, although the company highlighted the trial’s overall positive results. 

  • Image attribution tooltip
    Getty / Edited by BioPharma Dive

    A biotech startup launches with $38M to develop a cystic fibrosis gene therapy

    Carbon Biosciences believes its technology, which is based on parvoviruses, could allow for larger gene delivery and repeat dosing.

  • Pfizer takes stake in Lyme disease partner ahead of key study

    Valneva will receive $95 million from Pfizer to support development of a vaccine candidate as the French company’s COVID-19 work sputters.

  • Image attribution tooltip
    Sarah Silbiger via Getty Images

    FDA authorizes Pfizer, Moderna COVID-19 vaccines for young children

    The much-anticipated decision follows two days after a panel of independent experts unanimously recommended expanding the shots’ use.

    Updated June 19, 2022
    FDA
  • Image attribution tooltip
    Getty Images

    Roche Alzheimer's study fails in another setback to a long-tested hypothesis

    The failure is an upset not only to Roche, but also a blow to the wider Alzheimer’s research field, which has for years kept focus on a protein called beta amyloid.

  • Image attribution tooltip
    E+ via Getty Images

    Boehringer extends cancer dealmaking with right to buy biotech partner

    The German pharma company has secured an option to acquire Trutino Biosciences, two years after inking a research collaboration with the San Diego drug developer. 

  • Federal Trade Commission
    Image attribution tooltip
    Carol Highsmith. (2005). "The Apex Building" [Photo]. Retrieved from Wikimedia Commons.

    Pharma under the microscope as FTC considers new ways to review acquisitions

    At a two-day meeting, experts argued drug divestitures may not be enough to prevent market concentration. Economists and regulators also appeared worried by the effect of buyouts on innovation.

  • Image attribution tooltip
    Spencer Platt via Getty Images

    With biotech in retreat, Third Rock raises $1B for life sciences investing

    The fund, Third Rock’s sixth, comes amid a significant downturn in biotech stocks, which has raised questions about the viability of young drug startups.

  • Image attribution tooltip
    Dan Kitwood via Getty Images

    Pfizer study results show Paxlovid benefit less clear in lower-risk patients

    A closely watched study missed its goal, failing to prove the antiviral pill’s benefit in a broader population than the high-risk individuals for which it’s currently cleared.

  • Image attribution tooltip
    Sarah Silbiger via Getty Images

    FDA advisers recommend Pfizer, Moderna COVID-19 vaccines for youngest children

    Independent experts unanimously supported use of both shots in children aged 6 months to 5 years old, clearing the way for an FDA decision.

    Updated June 15, 2022
    FDA
  • Image attribution tooltip
    Alnylam Pharmaceuticals

    Alnylam wins FDA approval of rare disease drug in step toward profitability

    Amvuttra, a transthyretin amyloidosis medicine previously known as vutrisiran, is viewed by biotech analysts as important to the company’s goal of ending years of financial losses.

    Updated June 14, 2022
    FDA
  • FDA approves Lilly, Incyte drug for alopecia, but includes safety warning

    The partners’ JAK inhibitor Olumiant is the first systemic treatment for an autoimmune disease that causes hair loss. But known risks of heart attacks and cancer could complicate its launch. 

    FDA